Abbad A, Yellin T, Carre?o JM, McPartlan JS, Taluk. Self-amplifying RNA vaccines encoding chimeric and mosaic hemagglutinins confer immunity against phylogenetically diverse influenza A viruses. Cell Rep. 2026 Nov 6:118244
Seasonal influenza vaccines require annual reformulation due to antigenic drift and provide suboptimal protection. Here, we evaluate self-amplifying mRNA (samRNA) vaccines encoding chimeric (cHA) and mosaic (mHA) hemagglutinins representing influenza A virus HA phylogenetic groups 1 and 2. Following prime-boost immunization, group 1 cHA vaccines (cH8/1-cH5/1) elicit broad cross-reactive antibodies and confer complete protection against diverse H1N1 strains covering decades of antigenic drift. Group 2 vaccines (cH4/3-cH15/3 and mH10/3-mH14/3) provide comparable breadth against multiple H3N2 strains and heterosubtypic H7N9 challenge, with cHA samRNA showing superior cross-group protection. Protection is associated with Fc-mediated effector functions and CD4+ T cell responses, with minimal hemagglutination inhibition and neutralizing titers. Passive serum transfer confirms antibody-mediated protection independent of cellular immunity. Protective immunity is maintained at doses as low as 0.4 μg, demonstrating the dose-sparing advantage of the samRNA platform. These results support samRNA-delivered cHA and mHA antigens as promising candidates for broadly protective influenza vaccines.
See Also:
Latest articles in those days:
- Weekly US Influenza Surveillance Report: Key Updates for Week 45, ending November 14, 2026 11 hours ago
- Anatomical Compartmentalization in Chickens Drives Divergent H9N2 Influenza Evolution Toward Human Receptor Binding and Immune Escape 1 days ago
- Epidemiologic Variability and Clinical Severity Across 11 Influenza Seasons in Children 2 days ago
- Molecular Epidemiology of Clade 2.3.4.4b H5N1 High-Pathogenicity Avian Influenza in South Africa, 2025-2026 2 days ago
- Structural basis of avian-to-human receptor-binding adaptation in H9Ny influenza A virus hemagglutinin 2 days ago
[Go Top] [Close Window]


